06978.HK
Immunotech Biopharm Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 0.36
+1.41%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +8.5%
- EBIT
- +9.7%
- EPS
- +34.9%
- Free cash flow
- -18.0%
- Operating cash flow
- -23.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -20.5%
- EBIT
- +21.6%
- Net income
- -23.5%
- EPS
- -16.7%
- Free cash flow
- +27.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026